Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With
A phase 3 trial of Sacituzumab tirumotecan, Docetaxel, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) is a phase 3 interventional study registered as NCT06074588 by Merck Sharp & Dohme LLC, with 556 participants planned, started 2023-11-12 and due to reach its primary completion in 2027-05-10. Interventions recorded: Sacituzumab tirumotecan, Docetaxel, Pemetrexed. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A
Shares Sacituzumab tirumotecan, Pemetrexed, Merck & Co. (MSD), Small-cell lung cancer.
- TrialSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Sacituzumab tirumotecan, Pemetrexed, Merck & Co. (MSD), Small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P
Shares Sacituzumab tirumotecan, Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Shares Docetaxel, Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Sacituzumab tirumotecan, Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSafety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
Shares Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.